Sorry, you need to enable JavaScript to visit this website.

SYNERCID® (quinupristin, dalfopristin) Clinical Studies

CLINICAL STUDIES

COMPARATIVE TRIALS

Complicated Skin and Skin Structure Infections

Two randomized, open-label, controlled clinical trials of Synercid (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 Synercid; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 Synercid; n = 222 Comparator).

In the first study, 105 patients (45.9%) and 106 patients (48.0%) in the Synercid and Comparator arms, respectively, were found to be clinically evaluable. For the second study, these values were 113 (51.1%) and 120 (54.1%) patients in the Synercid and Comparator arms, respectively. Patients were found not to be clinically evaluable for reasons such as: wrong diagnosis, lower extremity infection in patients with diabetes or peripheral vascular disease since these infections were assumed to include aerobic gram-negative and anaerobic organisms, no specimen for culture obtained, insufficient therapy, no test of cure assessment, etc.

For the patients found to be clinically evaluable, in Study JRV 304 the success rate was 49.5% in the Synercid arm and 51.9% in the Comparator arm. In Study JRV 305, the success rates were 66.4% and 64.2% in the Synercid and Comparator arms, respectively.

Table 10 shows the clinical success rate (combined results from two clinical trials) in the clinically evaluable population. Due to the small numbers of patients in the subsets, statistical conclusions could not be reached.

Table 10: The Clinical Success Rate in the Clinically Evaluable Population
Cured or Improved
Infection TypeSynercidComparator
(n/N)(%)(n/N)(%)
Erysipelas (cellulitis)52/82(63.4)43/77(55.8)
Post-operative infections14/38(36.8)24/42(57.1)
Traumatic wound infection33/55(60.0)33/55(60.0)

SAFETY

Discontinuations of therapy because of adverse reactions which were probably or possibly due to drug therapy occurred more than four times as often in the Synercid group than in the comparator group. Approximately half of the discontinuations in the Synercid arm were due to venous adverse events. (See ADVERSE REACTIONS: Clinical Reactions: Skin and Skin Structure Studies.)

Keep out of the reach of children.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for SYNERCID®